Dr. Slavko Ivković – curriculum vitae, extract
Internal medicine specialist, nephrologist
Date of birth: 18 April 1946
1965 - 1970
Studied medicine at the University of Zagreb
1975 –1991
Clinic J. Kajfež, Zagreb, Nephrology and Haemodialysis
Since 1991
Poliklinik Svećnjak, Zagreb, Gynecology, Internal medicine und Radiology
Since 2004
Vice President and CSO Chief Scientific Officer of the Klinomed Institute
Berlin-Buch, Institute for applied Nanotechnology and Nanomedicine
Member of scientific advisory board of the European Academy for
Interdisciplinary Medicine (EAIM)
Since 2009
Scientific consultant at the REGIOPHARMA d.o.o.
In the past several years a lot of efforts I’ve been made in the development of a new
technology for the production of new natural agents and intensification of the existing drugs
efficacy. First promising results were obtained using micro and nanoparticles of the
tribomechanically activated zeolite (TMAZ), i.e. clinoptilolite. As a nontoxic natural zeolite,
clinoptilolite exhibit versatile adsorptive, cation-exchanger, dehydrating-rehydrating and
catalytic properties. Due to the well defined structure and catalytic activity it represents an
attractive model system for protein and enzyme mimetics. Its activity mechanisms are based
on biomedical effect influencing on intracellular processes using signal pathways. It seems
that clinoptilolite particles can trigger alterations in gene expressions by initiating signaling
events upstream of gene transactivation. On the basis of biophysical effect on signal
pathways, TMAZ posses the possibility to act on all membrane and intracellular cell
receptors. Many disease processes such as diabetes, heart disease, autoimmunity and cancer
arise from defects in signal transduction pathways. This fact highlights the critical importance
of signal transduction to biology as well as medicine.
After the first promising results, studies on TMAZ have been extended and focused on
the synthesis of TMAZ and other natural and synthetic agents. It was noticed that after the
tribomechanical processing, clinoptilolite structure degraded in a size and becomes active and
easily associated with another substances. That sort of capacity is not just limited on a certain
types of substances, but it can be applied on a wide spectrum of natural and synthetic agents.
In these new compounds the synergism of all active substances became intensified. This is the
crucial characteristic and one of the main contributions of the TMA technology since it offers
a possibility to increase the effect of existing natural and synthetic substances without
significant investments in further research and studies.
Another significant accomplishment can be viewed in the aspect of the production of
new high performance drugs without toxic and other side effects based on TMAZ active
substance and different natural substances. In that sense, the activity mechanisms of three
natural agents which were studied in the several studies concerning anti-HIV, antihypertension and anti-diabetes agents are presented in this review.
Beside these researches, different types of studies were performed on a several types
of tumors showing very promising results. In clinical observations only patients in terminal
stage of illness (after the unsuccessful treatment with chemotherapy and radiotherapy) have
been observed. These observations suggest that combined therapies based on TMAZ may be
particularly promising in tumors known to respond to immune treatment with interferon’s and
interleukins, like melanoma, renal cell cancer, lung cancer and grade II and III astrocytoma.
All non-clinical and clinical studies presented in this review are in detail specified in
the supporting documentation. Although, in this review and in some accompanied articles for
tribomechanically activated zeolite (clinoptilolite) the acronym TMAZ is used, some authors
preferred to use term “micronized zeolite (MZ)”, “activated (zeolite) clinoptilolite (AC)” or
“finely ground clinoptilolite”. In all cases the same substance, i.e. clinoptilolite activated
using TMA technology, was used.
Scientific Publications:
[1]
Jeric M., Ivkovic S., Zigo I., Kurpes Z., Panjan I.
Hämodynamische und Ultraschal Charakteristik, Prolapsus cusp. post. Valvulae
mitralis. Nationaler Kardiologie Kongress, Zagreb 1977 .
[2]
Molnar V., Ivkovic S., Varlaj V., Bluthochdruck bei Hämodialyse Patienten,
Internationaler Kongress Nephrologie, Struga 26- 28- IX 1977 Kongress
Zusammenfassung, 585-594, 1977.
[3]
Ivkovic S., Molnar V., Plavljanic Dj., Bubic Lj., Samarzija I., Rolle der ZyklinNukleotide bei Hämodialyse Patienten mit Bluthochdruck, Internationaler Kongress
Hypertension, Sarajevo, Zusammenfassung 81-84, 1980.
[4]
Ivkovic S., Molnar V., Plavljanic Dj., Samarzija I., Effect of Potassium on Aldosteron
and Plasma Rennin Activity, Simposio mitteleuropeo di nefrologia e dialisi, Gorizia,
1980.
[5]
Ivkovic S., Molnar V.,Plavljanic Dj., Bubic Lj., Samarzija I. , The effects of Potassium
in arterial hypertension in patients suffering from chronic renal failure, Acta
physiologica et pharmacologica Yugoslavica, 183-191, 1980.
[6]
Ivkovic S., Plavljanic Bubic Lj.Molnar V., Ratkovic Gusic I., Inhibierung von
Angiotensin I mit Saralasin. Zusammenfassung Symposium Hämodialysis und
Bluthochdruck, Zagreb 1980 :73-77.
[7]
Ivkovic S., Molnar V Plavljanic Dj ., Samarzija I., Bubic Lj., Aktivität von cGMP und
cAMP Nukleotiden bei Hypertension, XI Nationaler Kongress für Innere Medizin,
Osijek 1980
[8]
Plavljanic Dj., Ivkovic S., Molnar V., Ferle A., Vitale Lj., Visnjic I., Bubic Lj.,
Untersuchungen des Angiotensin II Rezeptor in mezangialen glomerular Zellen,
Zusammenfassung Symposium Hämodialyse und Bluthochdruck , Zagreb 1980 .89-93
[9]
Ivkovic S., Molnar V., Plavljanic Dj., Bubic Lj ., Samarzija I., The role of Cyclic
nucleotides in hypertension in patients from renal failure, XXXI th Congresso Nationale
della Societa Italiana di Nefrologia, Rimini, 1980.
[10] Molnar V., Ivkovic S., Bubic Lj., Pericarditis bei Hämodialyse Patienten. Symposium
Medizin und Technik, Zagreb 1980.
[11] Ivkovic S., Molnar V., Plavljanic dj. Bubic Lj., Samarzija I., Stimulation der Alpha und
Beta adrenergic Rezeptoren bei Bluthochdruck Patienten mit Chronic renal Insufiziens,
Zusammenfassung Symposium Hämodialyse und Bluthochdruck, S. 68 –72 Zagreb
1980
[12] Ivkovic S., Molnar V., Bubic Lj., Einfluss von Hyperparathyreidismus bei
Bluthochdruck-Hämodialyse Patienten, Zusammenfassung Nationaler Kongress
Nephrologie Beograd, 1981.
[13] Molnar V., Ivkovic S., Bubic LJ., Hämodynamische Störungen bei hämodialyse
Patienten, Nationaler Kongress der Nephrologie, Zusammenfassung S. 847-861, 1981.
[14] Ivkovic S., Molnar V., Samarzija I., Plavljanic Dj., Bubic Lj., Angiotensin II Activity at
the level of renal proximal tubules 8th International congress of nephrology Athena
1981.
[15] Plavljanic Dj., Molnar V., Ivkovic S., Bobinac A., Bubic Lj., The significance of
Angiotensin II in rat mast cell degranulation 8th International congress of nephrology
Athena 1981
[16] Ivkovic S., Molnar V., Plavljanic Dj., Bubic Lj., Samarzija I., Potassium activity on
Plasma Renin activity in patients treated by chronic renal insufficiency, XVIII Congress
of the European dialysis and transplant association. Paris 1981 .
[17] Ivkovic S., Molnar V., Bubic Lj., Samarzija I. Significance of cyclic nucleotides in
patients with hypertension treated by chronic intermittent hemodialysis, XVIII th
Congress of the dialysis and transplant association, Paris, 1981.
[18] Bubic Lj ., Molnar V ., Ivkovic S., Plavljanic Dj., Welche Rolle spielen Gene bei
Hypertension, XII Nationaler Kongress für innere, Medizin, Osijek 1981.
[19] Krpan A., Ivkovic S., Molnar V. , Bluthochdruck in Nephrologie, Nationaler Kongress
für Nephrologie, Dubrovnik 1981
[20] Krpan A., Ivkovic S., Goranic T ., Djumija Z., Molnar V., Bluthochdruck Diagnostik
und Therapie in der Praxis Kongress für Nephrologie, Dubrovnik 1981.
[21] Ivankovic S., Ivkovic S., Molnar V. Prostangladinae in Hypertension, Kroatische
Ärztezeitschrift, 104 (7-8) S.280-282, Zagreb 1982.
[22] Ivkovic S., Ivankovic S., Molnar V., Protaglandin levels in plasma of hypertensive
Patients on hemodialysis, XIX Congress of the European Dialysis and Transplant
Association. Madrid 1982.
[23] Bubic Lj., Samarzija I., Ivkovic S., Malnar V., Bluthochdruck Therapie und das Niveau
von Zyklic Nukleotiden bei Hämodialyse Patienten, Symposium für Pharmacology,
Zagreb 1983.
[24] Molnar V., Milutinovic S., Ivkovic S., 25 OH chalciferol in therapy of renal
osteodystrophy, 6th Donau Symposim for Nephrology, Opatija 1984
[25] Ivkovic S., Bubic Lj., Plavljanic Dj ., Molnar V., Aldosteron and the Retention of
Sodium in patients with chronic renal Insuficiency, 6th Donau Symposim for
Nephrology, Opatija 1984.
[26] Ivkovic S ., Bubic Lj., Molnar V. Hyperaldosteronismus bei Hämodialyse Patienten6th
Donau Symposium for Nephrology, Opatija 1984.
[27] Bubic Lj., Ivkovic S., Samarzija I, Malnar V., Rolle des Angiotensin II in proxymal
tubule III th Congress for Nephrology, Ljubljana 1985.
[28] Bubic Lj ., Samarzija I., Ivkovic S. Einfluss des Calcium bei Hämodialyse Patienten III
Congress for Nephrology, Ljubljana 1985.
[29] Bubic Lj. Ivkovic S., Milutinovic S., Molnar V. Effect of Ca antagonist blood pressure
control in chronic dialysis patients 23th Congres of the EDTA -European Renal
association, Budapest 1986
[30] Krpan A., Nadinic B., Stefovic A., Loncar S., Tomicic D ., Halle J., Molnar V. Ivkovic
S., Pavlovic D., Orsanic D. Cardial arythmans in patients on hemodialysis., 23th
Congress of the EDTA-European renal association, Budapest 1986
[31] Ivkovic S., Bubic Lj., Molnar V., Syndroma Hepatorenale - unsere klinische
Observation , Internationaler Kongress für Gastroenterologie, Zadar 1986
[32] Krpan A., Frank B., Nadinic-Safar B., Bozikov J., Halle J., Ivkovic S., Ergometrie bei
Hämodialyse Patienten, Analy Vol .6 1987 : 54-56
[33] Ivkovic S., Zabcic D., What is th role of antioxidants in malignant disease, New ways in
oncology, Treviso 1999
[34] Ivkovic S., Zabcic D., The Effect tribomechanically activated Zeolite (TMAZ) on
Total Antioxidans-Status of healthy individuals and patients with malignant disease,
XIth Biennial Meeting of the Society of Free Radical Research International, Paris
2002
[35] Ivkovic S., Zabcic D., Antioxidative Therapie: NanotechnologY Product TMA-Zeolite
Reduces oxidative Stress in Cancer and Diabetic patients, 9th Annual Meeting of the
Oxygen Society, San Antonio 2002, Medigence LLC .Chapel Hill USA
[36] Ivkovic S., Mannel M., Walraph E., Immunomodulatory effects of tribomehanically
activated zeolite (TMAZ) in secondary Immunodeficiency – a clinical pilot study,
SFRBM 2004-11th Annual Meeting of the Society of Free Radical and Medicine
Resort in St. Thomas ,US Virgin Islands
[37] Ivkovic S., Schulz J., Bendzko P., Tribomechanicaly activated zeolithe ( TMAZ ) as
an adjuvant cancer treatment-promising results from clinical case observation SFRBM
-2004 -11th Annual Meeting of the Society of Free Radical Biology and Medicine,
Resort in St Thomas, US Virgin Islands
[38] Ivkovic S., Erfahrungen in der Nahrungsergänzung mit tribomechanisch aktivierten
Zeolithen (TMAZ), DermaProf 2004, Wiesbaden 2004
[39] Ivkovic S. , Schulz,J. Bendzko ,P., Neue Erfahrungen bei der Anwendung von Megamin
im Alter 12. Jahrestagung der Deutschen Gesellschaft für Geriatrie Berlin 2830.10.2004, Abstract: European Journal of Geriatrics Vol. 6: 2004
[40] Ivkovic S., Deutsch U., Siberbach A., Walraph E., Mannel M., Supplementation with
the Tribomechanically Activated Zeolite Clinoptilolite in Immunodeficiency: Effects on
the Immune System, „Advances in Therapy“, Volume 21, No.2, March/April 2004
[41] Veröffentlichung des Buches “Oxidativer Stress – Risikofaktor Nr. 1 für Ihre
Gesundheit“, ISBN: 3-00-013116-7
[42] J.Schulz, K.Gulbin, H.Gulbin, S.Ivkovic und P.Bendzko, Neue Möglichkeiten bei der
Behandlung der Psoriasis vulgaris mittels neuartiger Antioxidanzien, 8. Wiener
Internationaler Geriatriekongress, 20.-23. April 2005
[43] Slavko Ivkovic, Thomas Baranek, Peter Bendzko, Jörg Schulz, TMAZ nanoparticles as
potential drugs influenzing the cellular signal transduction pathways, 2005 NSTI
Nanotechnology Conference & Trade Show, Nanotech 2005 May 8-12, 2005 Anaheim,
California, U.S.A.
[44] Slavko Ivkovic & Danko Brezak, Nanoparticles of the Thermo-mechanically Activated
Zeolite in the Design and Synthesis of New Drugs Generation, 2008 NSTI
Nanotechnology Conference & Trade Show, Nanotech 2008, June 1-6, 2008 Boston
U.S.A.
[45] Slavko Ivkovic & Danko Brezak,
An Innovative New Natural Anti-diabetic Agent with Intracellular Mechanisms of
Action 2nd International Conference on Drug Discovery and Therapy February 1st- 4th
2010, Dubai,UAE